Michigan Medicine Chooses SelectMDx Prostate Cancer Test to Reduce Biopsies

Michigan Medicine Chooses SelectMDx Prostate Cancer Test to Reduce Biopsies
The University of Michigan’s new prostate cancer risk clinic will use the SelectMDx test to diagnose the disease — a move it believes will reduce unnecessary biopsies. SelectMDx is a urine-based molecular test capable of identifying patients at low risk of developing prostate cancer. Its results help patients avoid having to undergo invasive and painful biopsies.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Lawrence Glickman says:

    While this new urine test is interesting and valuable it re in forces a disturbing trend. This is the trend to “watchful waiting”. In plain English this means that after cancer is discovered you can wait on treatment because the side effects are always possible and your age and other health conditions may mean that you die of something else first. I am categorically against this approach. Here is my primary reason. Today there are increasing numbers of less harmful treatments such as the Tookad system with no radiation recently approved for use in Mexico and under review at the FDA and it has passed FDA 3 tests at Sloan Kettering in NYC and on the verge of approval in Europe. There are others as well with great results using focal techniques for new low risk patients. There is no oncologist in the world that can tell a patient that while he “waits” metastases from the so called “Small Lesion” or “Slow Moving” organ confined tumor is not in progress. Therefore early detection and treatment has never made more sense. I am not a Doctor but a long term independent researcher. My father died of Prostate cancer over a 13 year period and my Brother recovered from the disease with early treatment.

Leave a Comment

Your email address will not be published. Required fields are marked *